Asensus Surgical (FRA:2TX) COGS-to-Revenue : 2.72 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Asensus Surgical COGS-to-Revenue?

Asensus Surgical's Cost of Goods Sold for the three months ended in Mar. 2024 was €2.81 Mil. Its Revenue for the three months ended in Mar. 2024 was €1.03 Mil.

Asensus Surgical's COGS to Revenue for the three months ended in Mar. 2024 was 2.72.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Asensus Surgical's Gross Margin % for the three months ended in Mar. 2024 was -172.12%.

Asensus Surgical COGS-to-Revenue Historical Data

The historical data trend for Asensus Surgical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical COGS-to-Revenue Chart

Asensus Surgical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

2.43

1.63

1.35

1.53

Asensus Surgical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															3.02	2.84	2.64	0.79	2.72

Asensus Surgical COGS-to-Revenue Calculation

Asensus Surgical's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	12.063	/	7.865
	=	1.53

Asensus Surgical's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.811	/	1.033
	=	2.72

Asensus Surgical (FRA:2TX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Asensus Surgical's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.811 / 1.033
	=	-172.12 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Asensus Surgical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (FRA:2TX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (FRA:2TX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ASXC:USA

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Asensus Surgical (FRA:2TX) Headlines

No Headlines